Daniel Boster

Mozart Therapeutics

Poster(s):

• W114 - Nonclinical Toxicology and Safety Studies of MTX-101, an Inhibitory KIR2DL X CD8 Targeting Bispecific CD8 Treg Modulator, Enabling Clinical Development as Therapeutic for the Treatment of Autoimmune Disease
  Wednesday, June 19, 2024

  7:30 AM – 7:30 PM PT